CoChat

InRange: Comparison of the second-generation basal insulin analogues glargine 300 u/ml and degludec 100 u/ml in persons with type 1 diabetes using continuous glucose monitoring-study design

Open access
Battelino, Tadej, Bosnyak, Zsolt, Danne, Thomas, Mukherjee, Bhaswati, Edelman, Steve, Pilorget, Valerie, Choudhary, Pratik, Renard, Eric, Bergenstal, Richard · 2020 · Diabetes Therapy

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Suboptimal glycaemic control among people with type 1 diabetes (T1D) is known to lead to long-term micro- and macrovascular complications and, unfortunately, it is still prevalent even in the most affluent societies. Although glycated haemoglobin monitoring is considered to be the gold standard for assessing glycaemic control, such monitoring is unable to reliably measure acute glycaemic excursions. Continuous glucose monitoring (CGM) has been shown to improve glucose control and reduce the incidence of hypoglycaemia, and also allow a more complete assessment of overall glycaemic control and hyper- and hypoglycaemic excursions. The use of CGM has led to time-in-range, which is the time that a patient is within the glycaemic range of 70 to 180 mg/dL, to be adopted as a treatment target. To date, only limited data comparing the second-generation insulins glargine 300 U/mL (Gla-300) and degludec 100 U/mL (IDeg-100) in people with T1D are available, and there is no CGM literature on comparisons of the use of CGM results to assess primary, secondary and tertiary endpoints. The aim of the InRange study was to address this unmet need. METHODS: InRange is a multicentre, randomised, active-controlled, parallel-group, 12-week, open-label, phase 4, comparative study. Adults with T1D will be randomised to receive once-daily Gla-300 or IDeg-100 by subcutaneous injection in the morning. Following an 8-week titration period, CGM data will be collected over 20 consecutive days. PLANNED OUTCOMES: The primary objective is to demonstrate that Gla-300 is noninferior to IDeg-100 in terms of glycaemic control [time-in-range ≥ 70 to ≤ 180 mg/dL (≥ 3.9 to ≤ 10 mmol/L)] and variability, as assessed using CGM, in adults with T1D. The results are expected to help confirm the utility of CGM in clinical practice in this population and provide insight into its application as an outcome measure in clinical practice. TRIAL REGISTRATION: NCT04075513.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-020-00781-6

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study design. Asterisk indicates telephone calls by investigators to monitor insulin titration weekly between site visits for all participants, unless investigators are attending the study site for sensor replacement. Participant has option to come to site on day −10 and day 74 for sensor replacement. CGM Continuous glucose monitoring, Gla-300 insulin glargine 300 U/mL, HbA1c glycated haemoglobin, IDeg-100 insulin degludec 100 U/mL, MDI multiple daily injection, QD once daily, R randomisation, SMPG self-monitored plasma glucose, T1D type 1 diabetes
Fig. 1 Study design. Asterisk indicates telephone calls by investigators to monitor insulin titration weekly between site visits for all participants, unless investigators are attending the study site for sensor replacement. Participant has option to come to site on day −10 and day 74 for sensor replacement. CGM Continuous glucose monitoring, Gla-300 insulin glargine 300 U/mL, HbA1c glycated haemoglobin, IDeg-100 insulin degludec 100 U/mL, MDI multiple daily injection, QD once daily, R randomisation, SMPG self-monitored plasma glucose, T1D type 1 diabetesCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 23

Metadata

Authors
Battelino, T., Bosnyak, Z., Danne, T., Mukherjee, B., Edelman, S., Pilorget, V., Choudhary, P., Renard, E., & Bergenstal, R.
Affiliations
  • University of Ljubljana (SI)
  • Kinderkrankenhaus auf der Bult (DE)
  • Sanofi (France) (FR)
  • King's College London (GB)
  • Park Nicollet Clinic (US)
Corresponding author
Battelino, Tadej
Venue
Diabetes Therapy
Published
2020-02-25
Volume
11
Issue
4
Pages
1017-1027
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W3007217485
Cited by
23
References
29
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 8 · 2022: 4 · 2021: 5 · 2020: 2
FWCI
3.58
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by-nc)
  • Figshare (submittedVersion, cc-by-nc)
  • Research Portal (King's College London) (submittedVersion, other-oa)
Funders
Sanofi, Paris, France (NCT04075513)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
type 1 diabetes, basal insulin analogues, continuous glucose monitoring, time in range, glycemic variability, glycemic control, non-inferiority, hypoglycemia, insulin dose adjustment, subcutaneous insulin injection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: InRange: Comparison of the second-generation basal insulin analogues glargine 300 u/ml and degludec 100 u/ml in persons with type 1 diabetes using continuous glucose monitoring-study design. https://app.cochat.ai/papers/10.1007/s13300-020-00781-6
The paper
Battelino, T., Bosnyak, Z., Danne, T., Mukherjee, B., Edelman, S., Pilorget, V., Choudhary, P., Renard, E., & Bergenstal, R. (2020). InRange: Comparison of the second-generation basal insulin analogues glargine 300 u/ml and degludec 100 u/ml in persons with type 1 diabetes using continuous glucose monitoring-study design. Diabetes Therapy. https://doi.org/10.1007/s13300-020-00781-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.